These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 9633990)

  • 1. Selective depletion of DNA precursors: an evolving strategy for potentiation of dideoxynucleoside activity against human immunodeficiency virus.
    Johns DG; Gao WY
    Biochem Pharmacol; 1998 May; 55(10):1551-6. PubMed ID: 9633990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the M2 subunit of ribonucleotide reductase in regulation by hydroxyurea of the activity of the anti-HIV-1 agent 2',3'-dideoxyinosine.
    Gao WY; Zhou BS; Johns DG; Mitsuya H; Yen Y
    Biochem Pharmacol; 1998 Jul; 56(1):105-12. PubMed ID: 9698094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2',3'-dideoxynucleosides.
    Gao WY; Johns DG; Mitsuya H
    Mol Pharmacol; 1994 Oct; 46(4):767-72. PubMed ID: 7969058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2',3'-dideoxynucleoside activities against replication of human immunodeficiency virus.
    Gao WY; Johns DG; Chokekuchai S; Mitsuya H
    Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8333-7. PubMed ID: 7667290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxyurea: mechanisms of HIV-1 inhibition.
    Lori F; Lisziewicz J
    Antivir Ther; 1998; 3 Suppl 4():25-33. PubMed ID: 10723506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic antiviral action of ribonucleotide reductase inhibitors and 3'-azido-3'-deoxythymidine on HIV type 1 infection in vitro.
    Giacca M; Borella S; Calderazzo F; Bianchi LC; D'Agaro P; Rampazzo C; Bianchi V; Reichard P
    AIDS Res Hum Retroviruses; 1996 May; 12(8):677-82. PubMed ID: 8744578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyurea for HIV infection.
    Zachary KC; Davis B
    AIDS Clin Care; 1998 Apr; 10(4):25-6, 32. PubMed ID: 11365149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug.
    Lori F; Lisziewicz J
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S193-7. PubMed ID: 10860905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracellular activation of 2',3'-dideoxyinosine and drug interactions in vitro.
    Kewn S; Hoggard PG; Henry-Mowatt JS; Veal GJ; Sales SD; Barry MG; Back DJ
    AIDS Res Hum Retroviruses; 1999 Jun; 15(9):793-802. PubMed ID: 10381167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural Insights into HIV Reverse Transcriptase Mutations Q151M and Q151M Complex That Confer Multinucleoside Drug Resistance.
    Das K; Martinez SE; Arnold E
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28396546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues.
    Bouchonnet F; Dam E; Mammano F; de Soultrait V; Henneré G; Benech H; Clavel F; Hance AJ
    J Virol; 2005 Jan; 79(2):812-22. PubMed ID: 15613309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxyurea to inhibit human immunodeficiency virus-1 replication.
    Romanelli F; Pomeroy C; Smith KM
    Pharmacotherapy; 1999 Feb; 19(2):196-204. PubMed ID: 10030769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyurea may enhance effectiveness of anti-HIV regimens presently in use.
    Murphy MJ
    Fac Notes (New Orleans La); 1998; 10(2):1-2. PubMed ID: 11365124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiation of inhibition of wild-type and mutant human immunodeficiency virus type 1 reverse transcriptases by combinations of nonnucleoside inhibitors and d- and L-(beta)-dideoxynucleoside triphosphate analogs.
    Maga G; Hübscher U; Pregnolato M; Ubiali D; Gosselin G; Spadari S
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1192-200. PubMed ID: 11257034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New data intensifies interest in hydroxyurea.
    Santiago LG
    GMHC Treat Issues; 1995 Sep; 9(9):1, 3-4. PubMed ID: 11362902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication.
    Lori F; Malykh A; Cara A; Sun D; Weinstein JN; Lisziewicz J; Gallo RC
    Science; 1994 Nov; 266(5186):801-5. PubMed ID: 7973634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The additive in vitro anti-HIV-1 effect of chloroquine, when combined with zidovudine and hydroxyurea.
    Boelaert JR; Sperber K; Piette J
    Biochem Pharmacol; 2001 Jun; 61(12):1531-5. PubMed ID: 11377382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement by hydroxyurea of the anti-human immunodeficiency virus type 1 potency of 2'-beta-fluoro-2',3'-dideoxyadenosine in peripheral blood mononuclear cells.
    Gao WY; Mitsuya H; Driscoll JS; Johns DG
    Biochem Pharmacol; 1995 Jul; 50(2):274-6. PubMed ID: 7632173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic studies (PD) of didanosine (ddI) alone and in combination with azidothymidine (AZT) in human T-cells; a stochastic biochemical approach to antiretroviral nucleoside drug combination in inhibiting HIV-reverse transcriptase (RT).
    Periclou AP; Nandy P; Avramis VI
    In Vivo; 2000; 14(3):377-88. PubMed ID: 10904870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of human immunodeficiency virus type 1 inhibition by hydroxyurea.
    Lori F; Lisziewicz J
    J Biol Regul Homeost Agents; 1999; 13(3):176-80. PubMed ID: 10560752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.